Immunic (IMUX)
(Real Time Quote from BATS)
$1.32 USD
+0.02 (1.54%)
Updated Mar 28, 2024 02:30 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMUX 1.32 +0.02(1.54%)
Will IMUX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for IMUX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMUX
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade
IMUX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?
Other News for IMUX
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Immunic receives notice of allowance from USPTO
Immunic to Participate in Investor and Scientific Conferences in March
Immunic And 2 Other Stocks Under $2 Insiders Are Buying